MedTrace Logo

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2023-02-14

No results posted yet for this study

Summary

This study will enroll volunteers in an open-format (outside hospital) setting, to complete novel data collection/analysis of biomarkers, facial images, and audio-recording to establish an optimal set of parameters to predict emergent cases of infection via an early warning score, along with actionable personalized information.

Conditions

  • Inflammatory Response

Interventions

DRUG

Pneumovax 23

At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

DRUG

Typhim VI

At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

OTHER

Saline

At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

Sponsors & Collaborators

  • Philips Healthcare

    collaborator INDUSTRY

  • US Department of Defense - Defense Threat Reduction Agency

    collaborator UNKNOWN

  • Texas A&M University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-08
Primary Completion
2022-12-21
Completion
2022-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346302 on ClinicalTrials.gov